However, many previous studies are non-European and were initiated several decades ago, failing to account for the new treatments and grading standards, including the introduction in 2016 of a novel tumor category: NET G3, i.e., well-differentiated tumors with Ki-67 > 20% [18,19]. This evidence concerns the gene MKI67 and neoplasm.